Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880060 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5879903 | 0.89 | LMNA (0.44) | LMNAMAPTKMT2AMEN1HTT | |
| SCHEMBL5879897 | 0.89 | LMNA (0.44) | LMNAMAPTKMT2AMEN1HTT | |
| SCHEMBL5879720 | 0.89 | MAPT (0.54) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5879717 | 0.89 | MAPT (0.54) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5879876 | 0.88 | LMNA (0.53) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5879875 | 0.88 | LMNA (0.53) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5880160 | 0.88 | LMNA (0.50) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5880164 | 0.88 | LMNA (0.50) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5879622 | 0.87 | LMNA (0.60) | ALDH1A1LMNAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026339-B2 | Inhibitors of HCV NS5B polymerase | PFIZER INC. | 2006-04-11 | — | — | US | disclosed |
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | PHARMACIA & UPJOHN COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154056-A1 | [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate | ACACB, HCCS, HAVCR2 | ALDH1A1 1095/4885LMNA 4281/4885MAPT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.